161 related articles for article (PubMed ID: 32855818)
1. The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.
Wang Y; Shen M; Cheng J; Sun X; Kaiser PK
J Ophthalmol; 2020; 2020():4924053. PubMed ID: 32855818
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept.
Xue Y; Qinhua C
Front Med (Lausanne); 2022; 9():835255. PubMed ID: 35252267
[TBL] [Abstract][Full Text] [Related]
3. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
[TBL] [Abstract][Full Text] [Related]
4. One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy.
Ye LH; Cai Y; Shi X; Wong IYH; Qu JF; Zhao MW; Ying X; Li XX
Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1455-1462. PubMed ID: 33146832
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data.
Qi HJ; Jin EZ; Zhao MW
Int J Ophthalmol; 2019; 12(1):51-57. PubMed ID: 30662840
[TBL] [Abstract][Full Text] [Related]
8. Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy.
Jeon YJ; Kim JH; Kim JW; Kim CG
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945034
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
10. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
12. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
13. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
15. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
[TBL] [Abstract][Full Text] [Related]
16. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
17. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
18. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
